Alpha-1 Antitrypsin Deficiency

This is a condition where your body doesn't make enough of a protein called alpha-1 antitrypsin. This protein helps protect your lungs from damage. When you don't have enough, it can lead to serious lung problems like emphysema, and sometimes liver disease.

Condition

What people with Alpha-1 Antitrypsin Deficiency report

Every report comes from a Lived member, sent anonymously.

Have you tried alpha 1-Antitrypsin for Alpha-1 Antitrypsin Deficiency?

NameHow it went

About Alpha-1 Antitrypsin Deficiency

What It Is

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition in which the body makes too little alpha-1 antitrypsin (AAT), or makes a faulty version of it. AAT is a protein produced in the liver that travels through the blood to the lungs. There it acts as a brake on a powerful enzyme that white blood cells release when they fight infection or irritation. Without enough AAT, that enzyme gradually damages the tiny air sacs in the lungs, leading to emphysema, a form of chronic obstructive pulmonary disease (COPD). The lungs are not the only organ involved. In some forms of AATD, the abnormal protein gets stuck inside liver cells instead of leaving them, which can injure the liver. This can cause jaundice in babies and scarring of the liver (cirrhosis) in adults. Rarely, AATD causes painful lumps or patches in the skin. When lung symptoms appear, they usually start between ages 20 and 50, earlier than typical COPD. Many people with AATD go undiagnosed for years or are first told they have asthma, while some people who inherit the condition never develop serious problems.

Causes & Risk Factors

AATD is caused by changes (variants) in a gene called SERPINA1, which carries the instructions for making AAT. Everyone inherits two copies of this gene, one from each parent. The usual version is called M. The most important deficiency variants are Z, which produces very little AAT, and S, which produces moderately less. The combination a person inherits shapes their risk. Two Z copies (ZZ) carry a high risk of both emphysema and liver disease. An S and a Z together (SZ) raise the risk of lung disease, particularly in people who smoke. People with one deficiency variant and one normal copy (MZ or MS) are carriers: they usually do not have the condition, although MZ carriers have a slightly higher risk of lung or liver problems, and any carrier can pass the variant to their children. When both parents are carriers, each child has a 1 in 4 chance of inheriting two deficiency variants. Genes set the underlying risk, but exposures largely determine how much lung damage occurs. Smoking speeds up emphysema dramatically in people with AATD, and dust, chemical fumes and air pollution also contribute. AATD affects about 1 in 1,500 to 3,500 people of European ancestry and is most common in people of Northern European background, but it occurs in every population.

How It's Diagnosed

Diagnosis starts with a simple blood test that measures the level of AAT. A level below normal suggests AATD, and a genetic test then confirms it by identifying which variants a person carries. The specific combination matters because it predicts risk and determines who may benefit from specific treatment. Some laboratories test the genes directly as the first step, especially when suspicion is high. Because the condition is easy to miss, guidelines encourage testing anyone diagnosed with COPD, adults whose asthma leaves lasting airway narrowing, and people with unexplained bronchiectasis (permanently widened, mucus-filled airways) or unexplained liver disease. Babies with prolonged jaundice or abnormal liver tests may also be tested. Once someone is diagnosed, parents, siblings and children are offered genetic counseling and testing. For people with confirmed AATD, breathing tests show how well the lungs are working. A key measure is FEV1 (forced expiratory volume in one second), the amount of air you can blow out forcefully in the first second, compared with what is expected for someone of your age, height and sex. A CT (computed tomography) scan, a detailed X-ray image of the chest, can show emphysema, and blood tests and liver imaging check for liver damage.

Treatment Options

There is no cure for AATD, but treatment can slow lung damage and manage its effects. The most important step is avoiding smoke. Quitting smoking, avoiding secondhand smoke and limiting exposure to dust and fumes at work protect the lungs more than any medicine can. People who already have lung disease receive the same care used for other forms of COPD: inhaled medicines that open the airways (bronchodilators), inhaled steroids for some people, vaccines to prevent infections that trigger flare-ups, pulmonary rehabilitation (a supervised exercise and breathing program) and oxygen when blood oxygen is low. Augmentation therapy is the one treatment aimed at AATD itself. It replaces the missing protein with AAT purified from donated human blood plasma, given as an intravenous infusion once a week for life, at a clinic or at home. Brands include Prolastin-C and Zemaira. It is approved for adults who have emphysema and a severe deficiency, not for carriers or people with normal or mildly reduced levels. A large trial found it slowed the loss of lung tissue seen on CT scans, but studies have not shown that it reduces flare-ups or extends survival, and it cannot repair damage that has already occurred. It also does nothing for the liver. Side effects are usually mild, such as headache or dizziness. Serious allergic reactions are uncommon but possible, especially in people with a low level of the antibody IgA who have antibodies against it. The weekly schedule and cost are real considerations to weigh with a lung specialist. For severe disease, surgery to remove the most damaged lung tissue or a lung transplant may be options. There is no medicine that reverses AATD liver disease; care focuses on monitoring and, when the liver fails, liver transplant. Your clinician can also advise whether you should limit or avoid alcohol.

What to Expect

The course of AATD varies more than for most inherited conditions. Some people with two deficiency variants have healthy lungs for life, especially if they never smoke, while others develop emphysema in their 30s or 40s. Being diagnosed before symptoms start is valuable, because avoiding smoke and workplace fumes can delay or prevent much of the lung damage. For people with lung disease, AATD is a long-term condition with gradual changes. Regular breathing tests track how quickly lung function is changing and help guide decisions about augmentation therapy. Staying physically active, keeping vaccinations current and treating chest infections early help many people maintain their daily routines. The liver needs attention too. About 1 in 10 babies with AATD develop liver problems, and about 15 percent of adults develop cirrhosis. AATD also raises the risk of a type of liver cancer, so people with liver involvement have periodic blood tests and imaging. Because AATD runs in families, a diagnosis often prompts testing of relatives and raises questions about having children. A genetic counselor can explain what test results mean for you and your family.

When to Seek Help

Ask about testing if you have COPD, asthma that does not fully improve with treatment, unexplained liver disease, or a relative with AATD or with COPD that started unusually early. If you have AATD, contact your care team promptly when breathlessness, cough or phlegm get noticeably worse, when you have a fever or other signs of a chest infection, or if you notice yellowing of the skin or eyes, a swelling belly or swelling in the legs. Seek emergency care for a severe flare-up in which breathing becomes very difficult.

Questions to Ask Your Doctor

  1. 1.What are my genetic test results, and what do they mean for my lung and liver risk?
  2. 2.Which tests will we use to monitor my lungs and liver, and how often?
  3. 3.Am I a candidate for augmentation therapy, and what benefit could I realistically expect?
  4. 4.Which of my relatives should be tested, and should we see a genetic counselor?
  5. 5.What should I avoid at home or at work to protect my lungs?

Last reviewed • Oct 2026

Educational content, not medical advice.